Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery
Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts…
Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts…
BenevolentAI has raised a massive second round of fundraising to expand the drug developing capabilities…
The artificial intelligence company BenevolentAI is collaborating with two UK charities to use AI to…
AI, or artificial intelligence, has taken root in biotech. In this article, we explore its newfound…
May 5, 2017, saw the first FDA approval for an amyotrophic lateral sclerosis (ALS) drug…
An algorithm based on the brain's self-organizing capacity has been developed in Germany that could…
Last week, worldwide leaders gathered at the Artificial Intelligence in Bioscience Symposium in London to…
BenevolentAI is leading the charge in artificial intelligence. We talked to Jackie Hunter, who is…
Artificial Intelligence can make clinical trials cheaper and faster, and this British start-up is about…